Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
December 8, 2025BloodOpen Access

Clinical efficacy and safety of daratumumab-carfilzomib based therapy in newly diagnosed multiple myeloma: A retrospective cohort analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

MXMan XuKQKun Qian

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows high complete response rates in newly diagnosed multiple myeloma, suggesting daratumumab-carfilzomib is a viable option without stem cell transplant.

Key Points

  • High overall response rate of 90.5% observed in patients with newly diagnosed multiple myeloma.
  • Patients receiving daratumumab-carfilzomib therapy showed complete response in 47.6% of cases within a median follow-up of 12.3 months.
  • Retrospective cohort study conducted at a single center with 21 participants, evaluating real-world efficacy and safety.
  • Results highlight that the daratumumab and carfilzomib combination is a safe and effective option for multiple myeloma patients not undergoing ASCT.

Cite This Study

Xu et al. (2025) studied this question.

synapsesocial.com/papers/69362f6e4fa91c937236e08ehttps://doi.org/10.1182/blood-2025-7579
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Efficacy and safety of daratumumab plus carfilzomib-based induction/consolidation/maintenance therapy with autologous stem cell transplantation in transplant-eligible ultra high-risk newly diagnosed multiple myeloma: Preliminary results2025
  2. 2Cytogenetic subgroup analysis of the advance trial: A randomized multi-center study of carfilzomib, lenalidomide and dexamethasone (KRd) with or without daratumumab (D) in patients with newly diagnosed multiple myeloma (NDMM)2025
  3. 3Safety and efficacy of carfilzomib-based combinations in relapsed/refractory multiple myeloma patients in a real-world Setting : Results of a french single academic center retrospective study.2025
  4. 4Efficacy and safety of aponermin-carfilzomib-dexamethasone-based regimens for relapsed/refractory multiple myeloma: A Phase 2 prospective multi-center study2025
  5. 5Daratumumab-based therapy for newly diagnosed multiple myeloma patients with renal impairment：a multicenter retrospective study from China2025